drugset / Trial / NCT04225676
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
NaSingle-groupOpen-labelTreatment
Summary
This was a multi-center Phase II study investigating the efficacy and safety of reinfusion of tisagenlecleucel in pediatric and young adult patients with acute lymphoblastic leukemia (ALL) who were treated with tisagenlecleucel and experience B cell recovery.
Timeline
- Start
- 2020-10-19
- Primary completion
- 2021-10-19
- Completion
- 2021-10-19
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to slow enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | 200000 cells/kg | — |
| Subject | Tisagenlecleucel | Cell therapy | 5e+06 cells/kg | — |
| Subject | Tisagenlecleucel | Cell therapy | 1e+07 cells | — |
| Subject | Tisagenlecleucel | Cell therapy | 2.5e+08 cells | — |